



EUROPEAN
HEMATOLOGY
ASSOCIATION



Ferrata Storti
Foundation

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Jennifer Mosebach,^{1*} Sofia Shah,^{2*} Stefan Delorme,¹ Thomas Hielscher,³ Hartmut Goldschmidt,² Heinz-Peter Schlemmer,¹ Stefan Schönland,² Ute Hegenbart^{2*} and Jens Hillengass^{2*}

Haematologica 2018
Volume 103(2):336-343

¹Department of Radiology, German Cancer Research Center, Heidelberg; ²Department of Medicine V, Multiple Myeloma Section, University of Heidelberg and ³Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany

JM, SS, UH and JH contributed equally to this work

ABSTRACT

Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe. To study possible predictors of survival, 79 patients were investigated using whole-body magnetic resonance imaging to assess the visible tumor burden before and after allogeneic stem cell transplantation. Statistical analysis of clinical and imaging parameters included Cox regression models and distribution of survival time estimates (Kaplan-Meier method). Log rank test was used to determine the prognostic impact of the presence of focal lesions on survival. A higher tumor burden according to the lesion count was associated with a shorter overall survival (univariable/multivariable Cox regression: 1st magnetic resonance imaging $P=0.028/P=0.048$; 2nd magnetic resonance imaging $P=0.008/P=0.024$). Focal infiltration pattern itself seemed to be an additional adverse prognostic factor for overall survival (2nd MRI $P=0.048$), although no definite cut-off could be defined. Kaplan-Meier estimates at 60 months of follow up show a significant difference (Log rank $P=0.04$) for overall survival rates between patients with focal infiltration (32%) and those without (75%). Since this subgroup of patients may benefit from maintenance therapy, adoptive immunotherapy, or local interventions, whole-body imaging is an appropriate and highly recommendable diagnostic approach for detection of prognostically relevant lesions before and after treatment.

Correspondence:

j.mosebach@dkfz-heidelberg.de

Received: July 11, 2017.

Accepted: December 5, 2017.

Pre-published: December 7, 2017.

doi:10.3324/haematol.2017.176073

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/103/2/336

©2018 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>,

sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



Introduction

In the era of emerging immunologic treatment options in hematology and oncology, one of the first approaches in this field, namely allogeneic stem cell transplantation (alloSCT) remains a widely disputed but still promising therapeutic option. Results from clinical trials comparing outcome after autologous and alloSCT in patients with multiple myeloma (MM) have been ambiguous. Whilst in some studies allogeneic transplantation in first-line therapy led to at least a superior progression-free survival (PFS), the outcome was similar or even inferior to autologous SCT in others.¹⁻⁶ In the relapsed setting only one small study was able to show a superior PFS.⁷ Nevertheless, alloSCT is being increasingly used in some European countries, especially as second-line treatment and beyond.⁸ In some of the studies, survival curves revealed a plateau with patients achieving a long-term remission interpreted by some researchers as cure. Treatment-related mortality, however, is high compared to autologous transplantation, ranging from 10% in some first-line studies to up to 33% in the relapsed setting. Therefore, the International Myeloma Working Group recommended alloSCT only for eligible patients with early relapse after autologous SCT and within the setting of clinical trials.⁹ This considered, it will be necessary to discriminate patients who will probably benefit from the treatment from those who will not. Measurement of tumor burden as a surrogate for possible

remission or relapse is an ongoing matter of debate and is mostly indirect, as through immunoglobulin production/free light chains, CRAB criteria etc. Quantification can also be attempted through the percentage of plasma cells in bone marrow, but this is prone to sampling errors due to a focal growth pattern, as found in a significant number of patients.¹⁰ Monitoring of minimal residual disease including multi-color flow cytometry (MFC) and next generation sequencing (NGS)-based detection provides prognostic information but comes with the same problem of potential sampling error.¹¹⁻¹³ To identify the localization of malignant foci in the organism, modern imaging techniques play a major role in diagnostics and follow up. As a consequence, these methods have been included in the updated diagnostic and response criteria.^{14,15} Whole-body magnetic resonance imaging (WB-MRI) is of great value in early diagnosis and detection of residual disease since it has been shown that bone marrow infiltration detected by MRI is of prognostic significance.¹⁶⁻¹⁸ Previously, an agreement between serological response and changes in imaging has been proven, and it has also been shown that residual focal lesions after therapy (autologous SCT) are of prognostic significance for overall survival (OS).¹⁹ Additionally, MRI has the advantage that it implies neither radiation exposure nor contrast agent administration and can therefore be performed repeatedly without harm.²⁰ In the present study, we examined bone marrow infiltration in WB-MRI in patients before and after allogeneic SCT in addition to clinical and molecular risk constellation. Our intention was to learn whether the number of focal lesions before alloSCT or the number of persisting focal lesions thereafter is a possible predictor of survival. Finally, MRI might help to identify patients who will benefit from this treatment, or, in the post-transplant setting, those who might need additional treatment.

Methods

Patient cohort

In this single-institution-imaging-study, 79 patients were evaluated and had undergone WB-MRI before and after alloSCT between 7/2004 and 9/2013. A total of 68 were in stage III (86%) and 11 in stage II (14%) according to Durie-Salmon.²¹ Study approval was obtained from the institutional review board of the University of Heidelberg/Germany, and informed consent was

Table 1. Therapy regime.

| Systemic therapy and transplantation | n | % |
|---|----|------|
| alloSCT after 1 st relapse | 20 | 25.3 |
| alloSCT after > 1 st relapse | 10 | 12.7 |
| Auto-allo SCT upfront | 16 | 20.2 |
| Auto-allo after 1 st relapse | 20 | 25.3 |
| Auto-allo after > 1 st relapse | 13 | 16.5 |
| | 79 | 100 |

allo: allogeneic; auto: autologous; n: number; SCT: stem cell transplantation.

waived due to the retrospective nature of this evaluation. For therapy regimes see Table 1. Clinical remission status is shown in Table 2.

Imaging protocol and evaluation

Diagnostic whole-body-MRI examinations were performed on 1.5T scanners (Avanto, Siemens Medical Solutions, Erlangen/Germany) including a coronal T1-weighted turbo-spin-echo sequence, coronal T2-weighted, fat-attenuated turbo-inversion-recovery magnitude (TIRM), and morphologic sagittal sequences (Table 3). No contrast medium was given. Protocol details have been previously published.^{17,22}

Focal lesions and diffuse infiltration patterns were assessed separately for each acquisition date by two radiologists, with 4 and 25 years of experience in oncologic imaging, blinded to the response, in consensus reading as previously described.^{19,23,24} Focal lesions were counted as myeloma infiltrates if they were hypointense in T1w as well as hyperintense in T2w fat-attenuated sequences, and >5 mm in diameter. *Online Supplementary information* is available.

Statistical analysis

For the analysis of prognostic significance of parameters at 1st MRI, PFS and OS were calculated from the date of allogeneic transplantation on, including 79 patients. OS was defined as time to death from any cause, and PFS as time to progression of disease or death, whichever occurred first. For parameters at 2nd MRI, OS and PFS were counted from the landmark time point 250 days after alloSCT. Patients who were in progression even before or at the 2nd MRI were excluded from this part of the analysis. The 2nd MRI was only included if it had been performed within 250 days of alloSCT.

Table 2. Remission status at baseline and follow up.

| | 1 st MRI | | 2 nd MRI | |
|------|---------------------|------|---------------------|------|
| | n | % | n | % |
| CR | 10 | 12.7 | 10 | 20.8 |
| nCR | 7 | 8.9 | 4 | 8.3 |
| VGPR | 8 | 10.1 | 10 | 20.8 |
| PR | 43 | 54.4 | 15 | 31.2 |
| MR | 3 | 3.8 | 1 | 2.1 |
| SD | 4 | 5.1 | – | – |
| PD | 4 | 5.1 | 8 | 16.7 |
| | 79 | 100 | 48 | 100 |

CR: complete remission; MR: minimal response; MRI: magnetic resonance imaging; n: number; nCR: near complete remission; PD: progressive disease; PR: partial response; SD: stable disease; VGPR: very good partial remission.




Figure 1. 2nd lumbar vertebra with focal remission after therapy. (A) 39-year-old patient before alloSCT; *magnification shows hypointense lesion in bone marrow (B) 6 months after alloSCT no focal lesion was detected. Also, note weight loss with reduction of abdominal and subcutaneous fat tissue after therapy.

Log-rank test was used to determine the prognostic impact of the presence of focal lesions on survival, and the distribution of survival times was estimated with the Kaplan-Meier method. Survival rates for PFS and OS at 24 and 60 months following alloSCT and landmark were compared. Prognostic impact was assessed with univariable and multivariable Cox regression models. Hazard ratio for the number of focal lesions was scaled to increments of 10 lesions. Multivariable models included the following additional covariates: Durie- Salmon stage, elevated LDH-levels, age, ISS (II/III vs. I), cytogenetic high-risk, treatment auto-alloSCT upfront each before alloSCT, and remission status according to the IMWG-criteria (VGPR or better) at the corresponding examination date of MRI assessment. A separate model was fitted for each time point (1st/2nd MRI) and MRI parameter (focal lesions yes vs. no/number of focal lesions). For multivariable models, missing values of clinical parameter values were imputed using multivariate imputation by chained equations as implemented in the R package based on 100 imputation runs.²⁵ All tests were two-sided; $P < 0.05$ was considered statistically significant. All analyses were carried out with statistical software R 3.2 (R Foundation for Statistical Computing, Vienna/Austria. URL <https://www.R-project.org/>).

Results

Clinical parameters

Mean time interval between 1st MRI and alloSCT was 29 days (range 0 -113). Response was assessed according to the guidelines of the International Myeloma Working Group adding “near complete remission” (Table 2).¹⁵ Median follow up was 83.5 months (72.0-113.6). Fifty-

Table 3. Imaging protocol.

| MRI-sequence | T1-w TSE cor | T2w-TIRM cor | T2-w FLASH sag |
|--------------|--------------|--------------|----------------|
| TR/TE | 627ms/11ms | 3340ms/109ms | 402ms/12ms |

cor: coronal; FLASH: T2*-weighted fast low angle shot; MRI: magnetic resonance imaging; sag: sagittal; TE: echo time; TIRM: turbo inversion recovery magnitude; TSE: turbo spin echo; TR: repetition time. Depending on the patient's height, acquisition included only proximal parts of the lower extremities.

seven (72.2%) patients had recurrent disease during follow up. In total 65 events for PFS and 51 deaths were observed (64.5%). Out of the 79 patients (median age 53 years/ range 29-65, 30 female/49 male patients) who had an initial MRI, 63 also completed the follow up examination, 48 of them in an acceptable time frame (< 250 days after alloSCT). Of those 48 patients, 39 had no progression until the 2nd MRI. Median time between alloSCT and 2nd MRI was 183 days (range 105- 238 days). For these 39 patients, 32 PFS events and 23 deaths were observed during follow up. Median follow up time in this subgroup was 76 months.

Univariable analysis of prognostic factors is shown in Table 4. A higher stage of disease according to the classification of Durie- Salmon (III versus II) resulted in earlier progression after alloSCT (HR 3.10, $P=0.016$). Prognostic factors before alloSCT influencing OS include an increase of LDH level (per 100U/L increment, HR 1.4, $P=0.025$). A less favorable outcome was also found for patients who did not undergo auto-alloSCT up front (HR 2.45, $P=0.039$).

Multivariate analysis (Table 4) supported an influence of the Durie- Salmon stage at 1st MRI on PFS (HR 3.48, $P=0.023$), and of the therapy regime on OS (HR 2.73,

Table 4. Clinical parameters influencing progression-free survival and overall survival.

| Clinical Parameters | Univariable Cox model | | Multivariable Cox model | |
|--|-----------------------|-------|-------------------------|-------|
| | HR (LCL-UCL) | P | HR (LCL-UCL) | P |
| PFS | | | | |
| Age | 1.02 (0.99-1.05) | 0.248 | 1.02 (0.99-1.06) | 0.232 |
| Durie-Salmon Stage: III vs. II | 3.10 (1.23-7.77) | 0.016 | 3.48 (1.19-10.16) | 0.023 |
| ISS: 2/3 vs. 1 | 0.98 (0.55-1.77) | 0.956 | 0.88 (0.47-1.65) | 0.687 |
| ISS: 2 vs. 1 | 1.23 (0.66-2.31) | 0.516 | | |
| ISS: 3 vs. 1 | 0.63 (0.26-1.50) | 0.295 | | |
| High LDH | 0.94 (0.49-1.82) | 0.862 | 1.13 (0.57-2.26) | 0.723 |
| Increase of LDH level (per 100 U/L increment) | 1.18 (0.90-1.55) | 0.221 | | |
| FISH: high risk vs. low risk | 1.41 (0.78-2.57) | 0.255 | 1.17 (0.62-2.21) | 0.633 |
| Status of remission at baseline: VGPR and better vs. other | 0.73 (0.42-1.27) | 0.269 | 0.70 (0.37-1.33) | 0.275 |
| Status of remission at 2nd MRI: VGPR and better vs. other | 0.50 (0.24-1.06) | 0.069 | 0.53 (0.17-1.69) | 0.285 |
| Therapy: other vs. auto-alloSCT upfront | 1.87 (0.95-3.68) | 0.071 | 1.68 (0.79-3.55) | 0.178 |
| OS | | | | |
| Age | 1.01 (0.98-1.05) | 0.515 | 1.00 (0.96-1.04) | 0.968 |
| Durie-Salmon Stage: III vs. II | 2.10 (0.76-5.85) | 0.154 | 2.83 (0.78-10.24) | 0.113 |
| ISS: 2/3 vs. 1 | 0.97 (0.49-1.93) | 0.941 | 0.96 (0.47-1.99) | 0.919 |
| ISS: 2 vs. 1 | 1.03 (0.49-2.15) | 0.939 | | |
| ISS: 3 vs. 1 | 0.85 (0.31-2.35) | 0.757 | | |
| High LDH | 1.53 (0.72-3.26) | 0.267 | 1.33 (0.58-3.08) | 0.500 |
| Increase of LDH level (per 100 U/L increment) | 1.40 (1.04-1.87) | 0.025 | | |
| FISH: high risk vs. low risk | 1.56 (0.79-3.10) | 0.202 | 1.23 (0.52-2.92) | 0.634 |
| Status of remission at baseline: VGPR and better vs. other | 1.13 (0.62-2.06) | 0.698 | 1.32 (0.65-2.71) | 0.443 |
| Status of remission at 2 nd MRI: VGPR and better vs. other | 0.99 (0.43-2.30) | 0.981 | 0.91 (0.31-2.66) | 0.861 |
| Therapy: other vs. auto-alloSCT upfront | 2.45 (1.05-5.76) | 0.039 | 2.73 (1.08-6.95) | 0.035 |

Analysis included univariable and multivariable Cox regression model. Results for models at 1st MRI (prior to alloSCT) are given, except for Status of remission at 2nd MRI, which is based on the model at landmark. Results for multivariable model are based on the model with number of focal lesions as MRI parameter. No relevant differences in results were found when considering presence of focal lesions (yes/no) as MRI parameter instead. Deletion 17p13 and translocation t(4;14) were considered high-risk cytogenetic aberrations. The influence of translocation t(14;16) was not investigated due to a high number of missing values. The only two patients with documented t(14;16) also had del17p13. AlloSCT: allogeneic stem cell transplantation; auto: autologous; FISH: fluorescence *in situ* hybridization; HR: hazard ratio; ISS: international staging system; LCL: lower 95% confidence level; LDH: lactate dehydrogenase; PFS: progression-free survival; OS: overall survival; UCL: upper 95% confidence level; U/L: units per litre; VGPR: very good partial response.

$P=0.035$). Other factors such as age, LDH, remission status and cytogenetic risk constellation did not reach statistical significance.

MRI findings

At initial imaging, focal lesions were detected in 66 out of 79 patients (83.5%), and diffuse infiltration patterns in 60 patients (76%). After alloSCT, myeloma-suspicious focal lesions were visible in 27 out of 39 patients (69.2%), none in 12 (30.8%), and 28 patients had signal alterations compatible with diffuse infiltration (71.8%). A figure with T1-weighted images of a patient with multiple lesions at various locations is included in the Online Supplementary Material.

Of the 39 patients without clinical progression, 8 had no lesions in neither the baseline nor the follow up MRI scan. In 27 patients, one or more lesions were found at baseline

and at the follow up scan. In 4 patients, one or more lesions were present at baseline and resolved after alloSCT. An example of a focal remission is shown in Figure 1, images of a patient with progressive disease in follow up MRI is included in the Online Supplementary Material.

Univariable regression analysis (Table 5) could not detect statistically significant influence of MRI findings on PFS. Statistical results for presence of one or more focal lesion after therapy and of increasing number of focal lesions at 1st and 2nd MRI suggested an effect with HR >1 but this did not reach statistical significance.

A higher number of focal lesions at baseline and follow up, on the other hand, were associated with a shorter OS (Table 5, HR 1.22, $P=0.028$; HR 1.46, $P=0.008$, respectively, per 10 lesion increase). Presence of at least one focal lesion after therapy also yielded a negative prognostic

effect on OS (Table 5, HR 2.98; $P=0.048$). This is also seen in the Kaplan-Meier plot for OS and presence of any focal lesion at second MRI, which is shown in Figure 2. Kaplan-Meier survival rates for PFS and OS at 24 and 60 months of follow up are presented in Table 6. If any focal lesion were detectable on the second MRI, the OS rate was 63% after 24 months and 32% after 60 months. If no focal lesions were detected (log-rank, $P=0.04$), 92% of the patients were alive after 24 months, and 75% after 60 months.

Multivariable analysis supported the adverse prognostic influence on OS for increasing number of lesions (by 10) at both time points (HR 1.24, $P=0.048$; HR 1.56, $P=0.024$, respectively). Furthermore, increased risk without reaching statistical significance was found for PFS and OS considering presence of focal lesion at 1st MRI (HR 1.96, $P=0.097$; and HR 2.26, $P=0.098$), and for higher numbers at baseline (PFS, increase by 10 lesions: HR 1.21, $P=0.058$).

Diffuse infiltration pattern showed no impact on PFS (1st MRI $P=0.720$, 2nd MRI $P=0.699$) or OS (1st MRI $P=0.151$, and 2nd MRI $P=0.238$).

Patients with decreasing numbers of focal lesions (19/39) between MRIs did not have a better prognosis than other patients with focal infiltration at baseline imaging. Patients with resolving lesions showed slightly better PFS than patients with no lesions at both MRIs but without statistical significance (HR 0.42 $P=0.280$). No statistically significant difference was found for patients with none versus persisting lesions (HR 1.41, $P=0.44$), meaning radiologically stable patients.

Discussion

Given that multiple myeloma is as yet not curable in the majority of patients, not even with autologous SCT, alloSCT remains a last resort in the attempt to definitely eradicate the disease. However, a relatively high treatment-related mortality and morbidity and a still significant percentage of relapsing patients has led to the recom-

mendation to apply this treatment only in eligible patients with early relapse after autologous SCT and within clinical trials.⁹ Hence, it is important to identify those patients who might benefit from alloSCT.

Prognostic significance of tumor burden

The intention of the current analysis was to study the prognostic relevance of focal lesions as a measure of tumor burden in multiple myeloma in the setting of alloSCT. MRI examinations before and after allogeneic stem cell transplantation were therefore retrospectively reviewed with a long follow up. Results of univariable and multivariable analyses verified that a higher tumor load at baseline as well as follow up-MRI is of adverse prognostic significance for OS. This is supported by indirect measure-




Figure 2. Kaplan-Meier graph for influence of presence or absence of focal lesions in 2nd MRI on OS. Censored patients are indicated with small vertical marks. Supplementary information is available online.

Table 5. Imaging findings.

| | Univariable Cox model | | Multivariable Cox model | |
|--|-----------------------|-------|-------------------------|-------|
| | HR (LCL-UCL) | P | HR (LCL-UCL) | P |
| PFS | | | | |
| MRI 1 | | | | |
| Presence of focal lesion | 1.56 (0.80-3.08) | 0.195 | 1.96 (0.89-4.31) | 0.097 |
| Increasing number of focal lesions by 10 | 1.15 (0.97-1.36) | 0.099 | 1.21 (0.99-1.47) | 0.058 |
| MRI 2 | | | | |
| Presence of focal lesion | 1.83 (0.83-4.03) | 0.131 | 1.40 (0.52-3.78) | 0.506 |
| Increasing number of focal lesions by 10 | 1.19 (0.90-1.57) | 0.223 | 1.19 (0.75-1.89) | 0.457 |
| OS | | | | |
| MRI 1 | | | | |
| Presence of focal lesion | 1.96 (0.83-4.60) | 0.123 | 2.26 (0.86-5.94) | 0.098 |
| Increasing number of focal lesions by 10 | 1.22 (1.02-1.45) | 0.028 | 1.24 (1.00-1.54) | 0.048 |
| MRI 2 | | | | |
| Presence of focal lesion | 2.98 (1.01-8.79) | 0.048 | 2.79 (0.84-9.33) | 0.095 |
| Increasing number of focal lesions by 10 | 1.46 (1.10-1.94) | 0.008 | 1.56 (1.06-2.28) | 0.024 |

Progression-free survival (PFS) and overall survival (OS). Univariable and multivariable analysis of hazard ratio (HR) are shown with lower and upper 95% confidence level (LCL and UCL). MRI1: 79 patients; MRI2: 39 patients.

ments of tumor burden, like increasing LDH-levels or a high M-component production rate, as being included in the Durie- and Salmon Staging system, which was used for these patients at the time of recruitment.

In patients who did not progress immediately after transplantation, the detection of a focal infiltration pattern (at least one focal lesion/ any lesion) in bone marrow after therapy seems to be an additional adverse factor. OS after 5 years was 75% in patients without focal lesions in second MRI, compared to 32% for patients with detectable lesions. This remarkable difference is in line with the research by Walker *et al.* who concluded that a higher number of focal lesions in untreated newly diagnosed patients was unfavorable for survival, although in our present study no cut-off point for number of lesions could be defined. Patients with resolving lesions resembling imaging response showed slightly better PFS without statistical significance, probably due to limited eligible patients with complete imaging. Patients with any focal lesion after therapy and especially a higher tumor load on MRI are at higher risk of progression and shorter OS, independently of molecular tumor activity. Therefore, patients might be selected for, and hopefully profit from, continuous therapy to prevent or at least delay relapse. Additionally, localized relapse has been shown to occur despite sustained molecular remission, which can be reliably detected through follow-up imaging.²⁶

Comparison to findings in PET/CT and autologous SCT

The results of the present analysis also support previous findings that residual lesions after autologous SCT are of adverse prognostic significance. This is true for MRI as well as PET/CT.² The mentioned results have led to the implementation of imaging findings into the updated recommendations for assessment of treatment response in patients with multiple myeloma.¹⁵ The rationale behind this recommendation is also that an assessment of minimal residual disease is performed usually on bone marrow samples acquired from the iliac crest. These samples, however, might miss accumulations of malignant cells i.e., focal lesions in other parts of the body. Since alloSCT aims to cure myeloma, the achievement and therefore the assessment of the deepest possible response is crucial. Our findings in the alloSCT setting support the results of Patriarca *et al.*, who evaluated 54 patients before and after allogeneic SCT with PET/CT and were able to show that patients with a complete remission in imaging have a sig-

nificantly longer PFS and OS than those in whom any PET-positive lesions had remained (2- year PFS: 51% versus 25%, $P=0.03$; 2-year OS: 81% versus 47%, $P=0.001$; 29). In recently published data of the IFM/DFCI Trial, PET/CT normalization before maintenance was also associated with better PFS and OS.³⁰

Combined results so far suggest that residual disease after therapy increases the risk of relapse, as we also previously discussed for patients after autologous SCT, although results for PFS were only of borderline statistical significance in our current study.¹⁹

Role of cytogenetic risk factors and therapy regime

Interestingly, some of the well-established risk factors like high risk cytogenetics by Fluorescence *in situ* hybridization and ISS had no prognostic effect in our cohort. Although we did observe an increased risk ($HR > 1$) for high-risk FISH, this did not reach statistical significance. Deletion 17p13 and translocation t(4;14) were considered high-risk cytogenetic aberrations. The influence of translocation t(14;16) was not investigated due to a high number of missing values because at the time of the first diagnosis of most of the patients (beginning in 2004) FISH was not yet standard of care in our department. It has nonetheless also been shown that a possible success of alloSCT is independent of the cytogenetic risk profile.³¹ Furthermore, a less favorable outcome was seen in patients who did not undergo auto-alloSCT up front. Poorer outcome in the relapsed setting has been previously reported by Franssen and colleagues, who also did not see any differences in outcome for patients with high risk cytogenetics, as was the case in our own investigation.³²

Limitations and future directions

A limitation of the present MRI study is the limited number of cases. It must be noted, however, that in comparison to other treatment options, few patients are eligible for alloSCT and, recruited in one of the biggest myeloma centers in the world, we herein present the biggest cohort with MR imaging to date. Also, we would like to discuss the mere morphologic evaluation applied in this study, which makes it difficult to separate active tumor lesions from pre-treated lesions without residual vital cells. Our own investigations (not published) which attempt to differentiate between these types of lesions have been unsuccessful to date, and caution is advised as progression can arise from inactive cystic-transformed

Table 6. Survival rates.

| | Focal lesion | Follow up (time/months) | PFS Survival rates (LCL-UCL) | OS Survival rates (LCL-UCL) |
|-------|--------------|-------------------------|------------------------------|-----------------------------|
| MRI 1 | yes | 24 | 0.34 (0.24-0.48) | 0.62 (0.51-0.75) |
| | | 60 | 0.16 (0.09-0.29) | 0.36 (0.26-0.51) |
| | no | 24 | 0.54 (0.33-0.89) | 0.77 (0.57-1.00) |
| | | 60 | 0.37 (0.18-0.77) | 0.68 (0.47-1.00) |
| MRI 2 | yes | 24 | 0.16 (0.07-0.39) | 0.63 (0.47-0.84) |
| | | 60 | 0.16 (0.07-0.39) | 0.32 (0.18-0.56) |
| | no | 24 | 0.50 (0.28-0.88) | 0.92 (0.77-1.00) |
| | | 60 | 0.37 (0.17-0.83) | 0.75 (0.54-1.00) |

Abbreviations: see Table 4.

lesions as well. Furthermore, repopulating blood-building bone marrow in vertebrae or even in long bones can morphologically resemble focal myeloma lesions and makes interpretation challenging. Functional MRI sequences such as diffusion weighted imaging (DWI) were not regularly available in this study, but are highly recommended in a scientific setting. Since the use of contrast agents is limited in myeloma patients, due to renal impairment as a potential symptom of the disease, DWI seems especially promising. It does not require contrast agents, but can still give qualitative and quantitative information about the bone marrow and has been shown to be a useful technique for detecting diffuse and multifocal marrow infiltration in patients with myeloma, with equal or higher sensitivity, when compared to PET.^{33,34} According to Cassou-Mounat *et al.* the detection rate of PET can be improved by the implementation of 18F-fluorocholine in diagnostics. In their pilot study, the recent metabolic tracer could detect more lesions compared to 18F-fluorodeoxyglucose.³⁵ Further studies are needed, and we are currently seeking to assess the development and remission of lesions in DWI and PET in this context in our institutions.

In addition to focal infiltration, diffuse bone marrow infiltration is seen in many myeloma patients. In our cohort, we could not detect an impact of a diffuse infiltration pattern on the patients' outcome. Although conven-

tional MRI has previously been shown to be more accurate than FDG PET/CT for the detection of diffuse marrow infiltration, due to the possible reconstitution of the bone marrow after previous therapy and transplantation, pathological or therapeutically induced diffuse signal changes could not be reliably distinguished.³⁶ Therefore, further analysis will surely be a topic of future research.

Conclusion

In general, it seems that a focal infiltration pattern and an increased tumor load represented by increasing focal myeloma bone marrow lesions, shortens OS. In conclusion, we recommend imaging using whole-body MRI before and after allogeneic SCT, since patients with prognostically relevant lesions and higher tumor burden before and after treatment independently of serological response may benefit from maintenance therapy, donor lymphocyte infusions (DLI), or local interventions to consolidate remission.

Funding

We gratefully acknowledge the German Research Foundation (*Deutsche Forschungsgemeinschaft*) for Research/Grant Support (*JM*) as part of the CRC/Transregio 79.

References

- Bruno B, Rotta M, Patriarca F, *et al.* A comparison of allografting with autografting for newly diagnosed myeloma. *N Engl J Med.* 2007;356(11):1110-1120.
- Bjorkstrand B, Iacobelli S, Hegenbart U, *et al.* Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol.* 2011;29(22):3016-3022.
- Gahrton G, Iacobelli S, Bjorkstrand B, *et al.* Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood.* 2013;121(25):5055-5063.
- Garban F, Attal M, Michallet M, *et al.* Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. *Blood.* 2006;107(9):3474-3480.
- Krishnan A, Pasquini MC, Logan B, *et al.* Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. *Lancet Oncol.* 2011;12(13):1195-1203.
- Rosinol L, Perez-Simon JA, Sureda A, *et al.* A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. *Blood.* 2008;112(9):3591-3593.
- de Lavallade H, El-Cheikh J, Faucher C, *et al.* Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. *Bone Marrow Transplant.* 2008;41(11):953-960.
- Sobh M, Michallet M, Gahrton G, *et al.* Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. *Leukemia.* 2016;30(10):2047-2054.
- Giralt S, Garderet L, Durie B, *et al.* American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. *Biol Blood Marrow Transplant.* 2015;21(12):2039-2051.
- Joshua DE. Tumor Burden. In: Berenson JR, ed. *Biology and management of multiple myeloma.* Totowa, NJ: Humana Press, 2004:127-136.
- Ladetto M, Ferrero S, Drandi D, *et al.* Prospective molecular monitoring of minimal residual disease after non-myceloablative allografting in newly diagnosed multiple myeloma. *Leukemia.* 2016;30(5):1211-1214.
- Paiva B, Cedena MT, Puig N, *et al.* Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma. *Blood.* 2016;127(25):3165-74.
- Sarasquete ME, Garcia-Sanz R, Gonzalez D, *et al.* Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. *Haematologica.* 2005;90(10):1365-1372.
- Rajkumar SV, Dimopoulos MA, Palumbo A, *et al.* International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol.* 2014;15(12):e538-e548.
- Kumar S, Paiva B, Anderson KC, *et al.* International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol.* 2016;17(8):e328-e346.
- Walker R, Barlogie B, Haessler J, *et al.* Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. *J Clin Oncol.* 2007;25(9):1121-1128.
- Hillengass J, Fechtner K, Weber MA, *et al.* Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. *J Clin Oncol.* 2010;28(9):1606-1610.
- Mariette X, Zagdanski AM, Guermazi A, *et al.* Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. *Br J Haematol.* 1999;104(4):723-729.
- Hillengass J, Ayyaz S, Kilk K, *et al.* Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. *Haematologica.* 2012;97(11):1757-1760.
- Derlin T, Peldschus K, Munster S, *et al.* Comparative diagnostic performance of (1)(8)F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. *Eur Radiol.* 2013;23(2):570-578.
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of

- measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer*. 1975;36(3):842-854.
22. Bauerle T, Hillengass J, Fechtner K, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. *Radiology*. 2009;252(2):477-485.
 23. Baur A, Stabler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? *Cancer*. 2002;95(6):1334-1345.
 24. Stabler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. *AJR Am J Roentgenol*. 1996;167(4):1029-1036.
 25. Stef van Buuren KG-O. mice: Multivariate imputation by chained equations in R. *J Stat Softw*. 2011;45(3):1-67.
 26. Byrne JL, Fairbairn J, Davy B, Carter IG, Bessell EM, Russell NH. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. *Bone Marrow Transplant*. 2003;31(3):157-161.
 27. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood*. 2009;114(10):2068-2076.
 28. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. *Blood*. 2011;118(23):5989-5995.
 29. Patriarca F, Carobolante F, Zamagni E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2015;21(6):1068-1073.
 30. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. *J Clin Oncol*. 2017;35(25):2911-2918.
 31. Kroger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. *Biol Blood Marrow Transplant*. 2013;19(3):398-404.
 32. Franssen LE, Raymakers RA, Buijs A, et al. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. *Eur J Haematol*. 2016;97(5):479-488.
 33. Pawlyn C, Fowkes L, Otero S, et al. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? *Leukemia*. 2016;30(6):1446-1448.
 34. Sachpekidis C, Mosebach J, Freitag MT, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. *Am J Nucl Med Mol Imaging*. 2015;5(5):479-492.
 35. Cassou-Mounat T, Balogova S, Nataf V, et al. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. *Eur J Nucl Med Mol Imaging*. 2016;43(11):1995-2004.
 36. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. *Haematologica*. 2007;92(1):50-55.